Vitae Pharmaceuticals (VTAE) Tops Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St futures muted as bond yields resume climb; Walmart drops after results
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Vitae Pharmaceuticals Reports First Quarter 2016 Operating and Financial Results
May 10, 2016 4:01 PM EDTProof-of-concept data for VTP-38543 expected in the second half of 2016
Conference call scheduled for 4:30 p.m. EDT today
FORT WASHINGTON, Pa., May 10, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today reported its operating and financial results for the quarter ended March 31, 2016.
Jeff Hatfield, President and Chief Executive Officer of Vitae, commented, The highlight of the first quarter was the positive top-line results from Vitaes Phase 2a proof-of-concept clinical trial of VTP-43742, our wholly owned, first-in-class RORt inhibitor, in... More
